Bionest Partners Finance
  • EXPERTISE
    • Capital Raising
    • Partnership
    • M&A
    • Valuation Advisory
  • ABOUT US
  • TRANSACTIONS
  • CONTACT US
  • EN
  • FR
Select Page

TRANSACTIONS

Recent Selected Transactions

2022 : TechnoConcept secures 4.4M€ financing and secondary buy-out

2022 : TechnoConcept secures 4.4M€ financing and secondary buy-out

2022 : Harmony Biosciences acquires Bioprojet’s Wakix XR US licensing rights

2022 : Harmony Biosciences acquires Bioprojet’s Wakix XR US licensing rights

2021 : Novadip 21M€ series B1 financing

2021 : Novadip 21M€ series B1 financing

2021 : Robocath secures 15M€ financing with EIB

2021 : Robocath secures 15M€ financing with EIB

2020 : Robocath 40M€ series C financing

2020 : Robocath 40M€ series C financing

2020 : European Licensing-out Advisory for Catabasis Pharmaceuticals

2020 : European Licensing-out Advisory for Catabasis Pharmaceuticals

2019 : Beaver Visitec acquires Arcadophta

2019 : Beaver Visitec acquires Arcadophta

2019 : FineHeart 5M€ bridge financing

2019 : FineHeart 5M€ bridge financing

2019 : Senior Assist 20M€ growth financing

2019 : Senior Assist 20M€ growth financing

2018 : Endo-Pharmaceuticals acquires Bioprojet’s Wakix commercial rights in Canada

2018 : Endo-Pharmaceuticals acquires Bioprojet’s Wakix commercial rights in Canada

2018 : Licensing-out Advisory for Acteon

2018 : Licensing-out Advisory for Acteon

2017 : Harmony Biosciences acquires Bioprojet’s Wakix commercial rights in the US

2017 : Harmony Biosciences acquires Bioprojet’s Wakix commercial rights in the US

2016 : AFM Telethon sells Trophos’ Olesoxime commercial rights to Roche Pharmaceuticals

2016 : AFM Telethon sells Trophos’ Olesoxime commercial rights to Roche Pharmaceuticals

Bionest Partners Finance has performed an extensive number of Financial Advisory projects for Healthtech startups and specialty Pharma companies (fairness opinion, business plan, deal structuring).

  • Follow